Mandate

Vinge advises Tele2 in the merger with Com Hem

Tele2 AB (publ) and Com Hem Holding AB (publ) announced on 10 January 2018 that they have agreed on a combination through a statutory merger in accordance with the Swedish Companies Act.

The combined company will be a leading integrated connectivity provider by combining an award-winning mobile network with the fastest national fixed network and the widest range of content in the market. The combination is conditional upon, inter alia, approval from the relevant competition authorities and approval of the merger from the shareholders in Tele2 and Com Hem. The merger is currently expected to be completed in the second half of 2018.

Vinge’s team primarily consists of Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Amanda Knutsson and Annika Nyberg Ekenberg (capital markets), Marcus Glader, Johan Karlsson, Emma Johansson, Grant McKelvey and Sebastian Örndahl (competition and regulatory), Louise Brorsson Salomon, Helena Håkansson and Lionardo Ojeda (financing) as well as Fredrik Dahl and Fredrik Gustafsson (employment).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025